Korea's KOSDAQ index closed at 1,203.84 on April 24, 2026 — the first close above the 1,200 mark since August 4, 2000. That's 25 years and 8 months of waiting for a number that once seemed permanently out of reach.
Why it matters
This isn't just a psychological milestone. During the dot-com bubble, KOSDAQ peaked at 2,925.20 on March 10, 2000. Today's 1,200 level represents just 41% of that historic high — meaning Korean growth stocks have spent a quarter-century in structural recovery mode.
What drove the move
Two sectors led the charge: biotech and semiconductor component/materials suppliers (known in Korea as "sobujang").
Biotech heavyweights Samchundang Pharmaceutical (+8.29%) and Peptron (+10.08%) surged on expectations for overseas licensing deals. On the semiconductor side, SFA Semiconductor, KOH Young Technology, and Joo Sung Engineering rode a global tailwind — Tokyo's Nikkei 225 closed up 0.92% on Intel's Q1 earnings beat, signaling continued strength in the semiconductor supply chain.
The supply side: who bought, who sold
Foreign investors poured ₩732.1 billion (~$530M) into KOSDAQ. Institutions added ₩187.3 billion. But retail investors sold ₩901.1 billion — essentially absorbing the entire institutional inflow. Retail treated 1,200 as a ceiling, not a floor. That matters in a market where individuals dominate trading volume.
Three scenarios for KOSDAQ's near-term direction
- Bull case (30%): Foreign buying sustains 3+ sessions, biotech licensing deals confirmed → targets 1,250–1,300
- Base case (50%): Technical pullback to 1,180–1,200, retest required before breakout is confirmed
- Bear case (20%): U.S.-China trade escalation reverses foreign flows; USTR Section 301 semiconductor hearing (May 8) adds uncertainty
Bottom line
A 25-year resistance level does not automatically become support in one session. I'm watching for 3 consecutive sessions of foreign net buying and a successful retest of 1,200 before adding KOSDAQ exposure. Biotech requires actual licensing announcements — not just momentum. Sobujang plays are more structurally grounded but carry USTR tariff risk.
For the full Korean-language analysis including historical data tables, sector breakdown, and a 5-point position checklist, visit Snakestock.
Top comments (0)